Top Page
Aquestive Therapeutics
(NASDAQ:AQST)
Aquestive Therapeutics (AQST) vs. SPDR S&P 500 ETF (SPY)
Aquestive Therapeutics Business Overview & Revenue Model
Aquestive Therapeutics Earnings Call Summary
Aquestive Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 44.13M | 57.56M | 50.58M | 47.68M | 50.83M | 45.85M |
| Gross Profit | 26.96M | 39.69M | 29.75M | 28.29M | 35.84M | 32.88M |
| EBITDA | -44.74M | -26.62M | 1.18M | -39.58M | -45.11M | -39.15M |
| Net Income | -65.04M | -44.14M | -7.87M | -54.41M | -70.54M | -55.78M |
Balance Sheet | ||||||
| Total Assets | 93.70M | 101.42M | 57.42M | 55.67M | 61.99M | 62.88M |
| Cash, Cash Equivalents and Short-Term Investments | 60.54M | 71.55M | 23.87M | 27.27M | 28.02M | 31.81M |
| Total Debt | 126.26M | 38.00M | 33.32M | 57.49M | 56.42M | 40.48M |
| Total Liabilities | 166.29M | 161.58M | 163.91M | 174.23M | 144.13M | 111.38M |
| Stockholders Equity | -72.59M | -60.16M | -106.49M | -118.55M | -82.13M | -48.50M |
Cash Flow | ||||||
| Free Cash Flow | -50.02M | -35.92M | -7.38M | -12.31M | -33.89M | -45.98M |
| Operating Cash Flow | -49.68M | -35.76M | -6.38M | -9.79M | -32.98M | -45.46M |
| Investing Cash Flow | -337.00K | -159.00K | -995.00K | -2.52M | -913.00K | -517.00K |
| Financing Cash Flow | 20.69M | 83.59M | 3.97M | 11.56M | 30.11M | 28.46M |
Aquestive Therapeutics Technical Analysis
Aquestive Therapeutics Risk Analysis
Aquestive Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $439.08M | 3.32 | 30.24% | ― | -22.74% | ― | |
60 Neutral | $562.53M | ― | 23.44% | ― | -3.48% | 36.57% | |
56 Neutral | $598.82M | ― | 77.48% | ― | -24.38% | -94.72% | |
55 Neutral | $58.19M | ― | -8.65% | ― | -6.79% | 61.56% | |
54 Neutral | $193.38M | ― | -57.22% | ― | -27.40% | -475.41% | |
51 Neutral | $8.02B | -0.31 | -43.38% | 2.24% | 22.31% | -2.14% | |
48 Neutral | $290.66M | ― | -76.41% | ― | 0.47% | -430.88% |
Aquestive Therapeutics Corporate Events
On September 8, 2025, Aquestive Therapeutics presented an investor presentation at the H.C. Wainwright 27th Annual Global Investor Conference. The presentation highlighted the company’s progress with its product candidates, including Anaphylm and AQST-108, and discussed potential market opportunities and regulatory challenges. The company aims to position Anaphylm as a novel oral administration of epinephrine, pending FDA approval, and anticipates growth in the U.S. epinephrine market. However, the company faces risks related to regulatory approvals, market acceptance, and financial resources.
On September 4, 2025, Aquestive Therapeutics announced that the FDA will not require an advisory committee meeting for their new drug application for Anaphylm™, a sublingual film for severe allergic reactions. This decision keeps the Prescription Drug User Fee Act target action date on track for January 31, 2026, potentially making Anaphylm the first FDA-approved, non-invasive epinephrine product. The company is preparing for a rapid launch upon approval, supported by recent financing activities, which could significantly impact the treatment landscape for anaphylaxis by offering a needle-free alternative.
On August 14, 2025, Aquestive Therapeutics announced an underwriting agreement for an offering of 21,250,000 shares of common stock at $4.00 per share, expected to raise $85 million. The proceeds will primarily fund the launch and commercialization of Anaphylm™, a sublingual film for severe allergic reactions, pending FDA approval, and support the company’s operations into 2027.
On August 13, 2025, Aquestive Therapeutics announced a $75 million strategic funding agreement with RTW Investments, contingent upon FDA approval of Anaphylm, a sublingual film for treating severe allergic reactions. This financing aims to support the potential commercialization of Anaphylm, strengthening the company’s financial position and offering a novel treatment option for patients. The agreement includes tiered revenue share payments to RTW based on Anaphylm’s net sales in the U.S., with payments ceasing upon reaching specified financial thresholds.
Aquestive Therapeutics announced its second quarter 2025 financial results and business updates, highlighting the FDA’s acceptance of their New Drug Application for Anaphylm, a sublingual film epinephrine product. The company is preparing for a potential U.S. launch in 2026 and is also pursuing regulatory engagements in Canada and the EU. Aquestive aims to address unmet needs in emergency allergy treatment with Anaphylm, which offers advantages over existing epinephrine therapies. Financially, the company reported a net loss of $13.5 million for the second quarter of 2025, attributed to decreased revenues and increased expenses.
On June 16, 2025, Aquestive Therapeutics announced that the FDA accepted its New Drug Application for Anaphylm™, an orally delivered epinephrine for treating severe allergic reactions, with a PDUFA target action date set for January 31, 2026. If approved, Anaphylm would be the first oral epinephrine option in the U.S., potentially transforming anaphylaxis care by addressing barriers such as fear of administration and the inconvenience of carrying bulky devices.
On June 11, 2025, Aquestive Therapeutics, Inc. held its Annual Meeting of Stockholders, where key decisions were made. Daniel Barber and Timothy E. Morris were elected as Class I members of the Board of Directors for a three-year term. Additionally, the stockholders approved executive compensation on a non-binding advisory basis and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.